Zheng Zhao

Zheng Zhao is a Post-doctoral Fellow working in the Wang Lab. He received his Bachelor and Ph.D. degree from Harbin Medical University in 2011 and 2016, respectively. During 2016 to 2022, he worked at the Beijing Neurosurgical Institute, working on establishing the molecular classification of gliomas and developing biomedical databases. He joined the Wang lab in December 2022 as a Post-doctoral Fellow, working on exploring tumor immune microenvironment and heterogeneity.

Address:

Room 4573, Academic Building
Department of Chemical and Biological Engineering
Hong Kong University of Science and Technology (HKUST)
Clear Water Bay, Kowloon,
Hong Kong Special Administrative Region, China

E-mail:zzhaobjni@ust.hk

Academic Background

• Doctor of Philosophy, Biomedical Engineering, Harbin Medical University, 2011/09-2016/06.
• Bachelor of Science, Biotechnology, Harbin Medical University, 2006/09-2011/06.

Past Scientific Experience

• 2021/12-, Associate Research Fellow, Beijing Neurosugical Institute.
• 2019/01-2021/11, Assistant Researcher fellow, Beijing Neurosugical Institute.
• 2016/08-2018/12, Intern Researcher fellow, Beijing Neurosugical Institute.

Publications

Journal Articles

• Lingxiang Wu#, Wei Wu#, Junxia Zhang#, Zheng Zhao#, Liangyu Li. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discovery. 2022 Dec 2, 12(12):2820-2837.
• KeNan Zhang#, Zheng Zhao#, Jing Chen#, Zhaoshi Bao#, RuiChao Chai#, Zhiyan Sun, Lingxiang Wu, Zhiliang Wang, Hanjie Liu, Quanhua Mu, Huimin Hu, Fan Zeng, Zheng Wang, Guanzhang Li, Yuanhao Chang, Qiangwei Wang, Fan Wu, Ying Zhang, Yuqing Liu, Chunjie Jiang, Ulf Dietrich Kahlert, DoHyun Nam, Wei Zhang, Chunsheng Kang*, Jiguang Wang*, Rongjie Tao*, Qianghu Wang* and Tao Jiang*. MET fusions and splicing variants convergently defne a subgroup of glioma sensitive to MET inhibitors. Holistic Integrative Oncology. 2022 Nov 20, (2022)1:18.
• Zheng Zhao#, Ke-Nan Zhang#, Zhiyan Sun#, ChanglinYang#, QiangweiWang, Guanzhang Li, ZhiliangWang, Fan Zeng, Ruichao Chai, Zenghui Qian, ZhengWang, Yanwei Liu, Wenping Ma*, FanWu* and Tao Jiang*. WES data from 286 diffuse gliomas under the 2021 who classifcation of tumors of the central nervous system. Scientific Data. 2022 Nov 11, 9(1):692.
• Fanlin Meng#, Kenan Zhang#, Changlin Yang#, Yan Peng, Kenan Zhang, Quan Xu, Ruifang Ren, Yiming Zhou, Yimin Sun, Yanze Li*, Hongyan Guo*, Yonghong Ren* and Zheng Zhao*. Prognostic pathways guide drug indications in pan-cancers. Frontiers in Oncology. 2022 Mar 14, 12:849552.
• Ying Zhang, Wenping Ma, Wenhua Fan, Changyuan Ren, Jianbao Xu, Fan Zeng, Zhaoshi Bao, Tao Jiang* and Zheng Zhao*.Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. Cell Death & Disease. 2021 Dec 8, 12(12):1140.
• Zenghui Qian#, Wenhua Fan#, Fanlin Meng#, Zhiyan Sun#, Guanzhang Li, You Zhai, Yuanhao Chang, Changlin Yang, Fan Zeng*, Ruichao Chai*, Fan Wu*, Zheng Zhao*.Molecular characterization and clinical relevance of ANXA1 in gliomas via 1,018 Chinese cohort patients. Frontiers in Cell and Developmental Biology. 2021 Nov 29, 9:777182.
• Shupeng Li#, Lulu Li#, Xiangqi Meng, Penggang Sun, Yi Liu, Yuntang Song, Sijia Zhang, Chuanlu Jiang*, Jinquan Cai* and Zheng Zhao*.DREAM: a database of experimentally supported protein-coding RNAs and drug associations in human cancer. Molecular Cancer. 2021 Nov 13, 20(1):148.
• Fan Wu#, Yan-Wei Liu#, Guan-Zhang Li#, You Zhai, Yue-Mei Fengx, Wen-Ping Ma, Zheng Zhao*, Wei Zhang*.Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. British Journal of Cancer. 2021 Jul, 125(2):255-264.
• Zheng Zhao#, KeNan Zhang#, Qiangwei Wang#, Guanzhang Li, Fan Zeng, Ying Zhang, Fan Wu, Ruichao Chai, Zheng Wang, Chuanbao Zhang, Wei Zhang, Zhaoshi Bao* and Tao Jiang*.Chinese Glioma Genome Atlas (CGGA): A comprehensive resource with functional genomic data from Chinese gliomas. Genomics Proteomics & Bioinformatics. 2021 Feb, 19(1):1-12.
• Fan Wu#, Zhiliang Wang#, Kuanyu Wang#, Guanzhang Li#, Ruichao Chai, Yuqing Liu, Haoyu Jiang, You Zhai, Yuemei Feng, Zheng Zhao* and Wei Zhang*. Classification of diffuse lower-grade glioma based on immunological profiling. Molecular Oncology. 2020 Sep, 14(9):2081-2095.
• Lulu Li#, Pengfei Wu#, Zhenyu Wang, Xiangqi Meng, Caijun Zha, Ziwei Li, Tengfei Qi, Yangong Zhang, Bo Han, Shupeng Li, Chuanlu Jiang*, Zheng Zhao* and Jinquan Cai*. NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer. Journal of Hematology & Oncology. 2020 Feb 28, 13(1):15.
• Fan Zeng#, Kuanyu Wang#, Xiu Liu and Zheng Zhao*. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma. Cell Communication and Signaling. 2020 Jan 6, 18(1):2.
• Zheng Zhao#, Kuanyu Wang#, Fan Wu#, Wen Wang, Kenan Zhang, Huimin Hu, Yanwei Liu and Tao Jiang*. circRNA disease: a manually curated database of experimentally supported circRNA-disease associations. Cell Death & Disease. 2018 May 1, 9(5):475.
• Zheng Zhao#,Fanlin Meng#, Wen Wang, Zheng Wang, Chuanbao Zhang and Tao Jiang*. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Scientific Data. 2017 Mar 14, 4:170024.